<DOC>
	<DOC>NCT00873431</DOC>
	<brief_summary>The main aim of this clinical study is to investigate the safety and tolerability of different dose strengths of IC47 up to 6 months after the first vaccination. A total of 32 healthy subjects (male or female) will participate in this clinical study. The subjects will be divided into 4 groups of 8 subjects each. Thirty (30) μg or 150 μg of IC47 will be administered three times in intervals of 42 days each.</brief_summary>
	<brief_title>Open-Label Study Assessing The Safety, Immunogenicity and Dose Response of IC47</brief_title>
	<detailed_description>This Phase 1 study will be conducted in four groups of 8 healthy subjects at a single study center. 32 subjects will be enrolled. The following table shows the design of the different study groups. The amount of protein shown in the table refers to the total protein content and is comprised of an equal amount of the three individual components.</detailed_description>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<criteria>Written informed consent Healthy adults ≥ 18 to &lt;/= 65 female subjects: post‐menopausal or practicing reliable methods of contraception during the study History of autoimmune diseases and malignancies. History of severe hypersensitivity reactions and anaphylaxis. Immunodeficiency due to immunosuppressive therapy. Infection with HIV, Hepatitis B or Hepatitis C. Pregnancy, lactation Vulnerable subjects</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Prevention of pneumococcal infections</keyword>
</DOC>